Eli Lilly’s weight-loss drugs no longer in shortage, FDA says
| The Washington Post and IBJ Staff
Lilly has been making the case since August that its tirzepatide-based drugs are now “commercially available,” which the FDA agreed on. But the agency warned that patients and prescribers might still experience “localized supply disruptions.”